| Routes Of Administration: | Oral |
| Class: | Orexin receptor antagonist |
| Cas Number: | 1637681-55-0 |
| Pubchem: | 139030979 |
| Chemspiderid: | 76117730 |
| Chembl: | 4776719 |
| Synonyms: | JNJ-61393215; JNJ-3215 |
| Iupac Name: | [(1''S'',4''R'',6''R'')-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone |
| C: | 23 |
| H: | 18 |
| F: | 4 |
| N: | 4 |
| O: | 2 |
| Smiles: | [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H] |
| Stdinchi: | 1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2 |
| Stdinchikey: | HUKWIAXQBOHZIX-USKNZQBOSA-N |
Tebideutorexant[1] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[2] [3] [4] It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA). Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans.[5] As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders. The drug was originated and developed by Janssen Pharmaceuticals.